<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the effect of isradipine, a blocker of L-type voltage-sensitive <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channels (VSCCs), on the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced release of <z:chebi fb="40" ids="18243">dopamine</z:chebi> in the rat striatum </plain></SENT>
<SENT sid="1" pm="."><plain>Perfusion of 200 micrograms/ml isradipine in the striatum did not alter extracellular <z:chebi fb="40" ids="18243">dopamine</z:chebi> concentrations monitored by microdialysis </plain></SENT>
<SENT sid="2" pm="."><plain>However, a marked increase (145-fold) in <z:chebi fb="40" ids="18243">dopamine</z:chebi> level during forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, developed by bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp>, was attenuated significantly by 37% by isradipine whereas the intensity of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, monitored by striatal blood flow, was unchanged </plain></SENT>
<SENT sid="3" pm="."><plain>These results suggest that isradipine attenuates the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced release of <z:chebi fb="40" ids="18243">dopamine</z:chebi> via blockade of L-type VSCCs on dopaminergic neurons </plain></SENT>
</text></document>